



Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Haoran Qian^{1†}, Na Yan^{2,3†}, Xiaotong Hu⁴, Junchang Jiang⁴, Zhengzheng Cao^{2,3} and Dan Shen^{2,3*}

¹Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China, ²Dian Diagnostics Group Co., Ltd., Hangzhou, China, ³Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, China, ⁴Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Keywords: gastrointestinal stromal tumors, molecular subtypes, clinicopathological features, next-generation sequencing, target therapy

OPEN ACCESS

Edited and reviewed by:

Michael Baudis,
University of Zurich, Switzerland

*Correspondence:

Dan Shen
shendan@dazd.cn

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Cancer Genetics and Oncogenomics,
a section of the journal
Frontiers in Genetics

Received: 16 May 2022

Accepted: 01 June 2022

Published: 28 June 2022

Citation:

Qian H, Yan N, Hu X, Jiang J, Cao Z
and Shen D (2022) Corrigendum:
Molecular Portrait of GIST Associated
With Clinicopathological Features: A
Retrospective Study With Molecular
Analysis by a Custom 9-Gene
Targeted Next-Generation
Sequencing Panel.
Front. Genet. 13:945357.
doi: 10.3389/fgene.2022.945357

A Corrigendum on

Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

by Qian H, Yan N, Hu X, Jiang J, Cao Z and Shen D (2022). *Front. Genet.* 13:864499. doi: 10.3389/fgene.2022.864499

In the original article, there was an error in affiliation 3. The corrected affiliation is “Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, China.”

In addition, the percentage of *KIT* mutations in GISTs was calculated incorrectly.

A correction has been made to **Abstract, Results**, sentence 2. The new sentence reads as follows:

“*KIT* mutations occurred most often in GISTs (94/106, 88.68%), followed by point mutations in *PDGFRA*.”

A correction has been made to **Results, Gene Mutation Distributions and Frequencies**, sentence 2. The new sentence reads as follows:

“*KIT* mutations occurred most often in GISTs (94 of 106 tumors, 88.68%), followed by the point mutation in *PDGFRA*.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Qian, Yan, Hu, Jiang, Cao and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.